Clinical trial
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
NCT00225173 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00225173 |
|---|---|
| Title | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease |
| Official title | A Phase II Trial of Stanford VI ± Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease With 3+ Risk Factors: the G6 Study |
| Lead sponsor | Stanford University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin Disease |
| Intervention type | Drug |
| Interventions | Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone |
| Enrollment | 45 |
| Start date | Oct 1, 2001 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 23, 2005 |
| Last update posted | Aug 27, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: